Blog

Press Releases

05/09/17

Discovery Names Matt Silver to SVP, Strategy, Engagement and Analytics
Download


05/12/16

Melissa Scherkoske Named a 2016 Healthcare Businesswomen’s Association Rising Star
Download


02/29/16

Rare Disease Day 2016
Download


02/23/16

Health care Marketing Leader Susan Johnson Named EVP, Director of Client Services, Discovery USA
Download


12/16/15

Discovery USA ‘All Systems Go’ Named One of PM360’s Top Innovations in 2015
Download


07/23/15

Jessica Goldstein 2015-2016 NAPW VIP Woman of the Year Circle
Download


03/06/15

Discovery USA Raises Funds and Awareness for Rare Disease Day
Download

Publications

April Meijer, SVP Advocacy, Named 2017 HBA Rising Star

Congratulations to our very own April Meijer, SVP Advocacy, a 2017 HBA Rising Star! April moves health forward by fostering relationships between patient advocates and our clients. We’re incredibly proud of April and thank her for her efforts to better the world every day!


Creative And Medical Science Communications: An Unexpected Pair

Creative is essential in medical science communications, but the two aren't always easy to put together. The work we see heading to health care professionals tend to either be highly creative focused or heavily scientific focused, thus begging the question, "Can there really be a happy marriage between medical science communications and creative?"

Jamie Dernik, our Vice President, Group Account Director, teaches us the 5 C's of getting a perfect blend of emotion and information in Creative And Medical Science Communications: An Unexpected Pair, a MediaPost article


Rare Disease Drugs Facing Questions Over Prices, Incentives

Rare diseases afflict 30 million Americans. Effectively marketing the orphan drugs that can treat these conditions means first understanding how drug pricing, R&D competition, and patient experience matter in the marketplace.

Drug approval numbers are up and biopharma continues to adapt. Still, “we may need to revisit the ODA to ensure that incentives remain to develop drugs for rare conditions and those incentives don't become diluted by loopholes,” says Nafeez Zawahir, MD, VP and scientific director at Discovery USA, in this Medical Marketing & Media article: Rare disease drugs facing questions over prices, incentives.

For a more in-depth look at the issues and further insights from Zawahir, check out the MM&M ebook Orphan Drug Marketing II: Data and expert insight for physician, patient, and payer outreach.


The Pharma Arms Race

Tongue twisters aside, the push for trendy and innovative vaccines have taken over the pharmaceutical community. While companies place their efforts into producing these niche vaccines, the rumble from the anti-vaxxer community continues to grow louder.
 
In the October 2015 issue of MM&M, our own Sean Trapani weighs in on the importance of leveraging that nifty invention called the World Wide Web, arguing that vaccine manufacturers shouldn’t take a passive role in the conversation.


support_images.jpg

Advocacy Matters

The health care industry is in flux. No longer is it enough to shape your strategies with data and a marketing plan alone. A decade ago, very few pharmaceutical companies were engaging in advocacy initiatives. Now, many either have, or are considering advocacy programming to help support business objectives. “Advocacy” remains a fluid concept, though. In response to this shift, advocacy has earned a place in the toolbox of many companies.

Beginning an advocacy program is a heavy lift. Are you ready internally? Have you chosen the right kind of advocacy, the right community partners? Do you and your partners understand your goals and metrics? The Discovery USA Advocacy Team can help you answer those questions and more. We have a unique approach—and it works.


white_papers_03.png

Discovery USA: An MM&M Top 100 Agency

MM&M profiled Discovery USA as part of its annual Top 100 Agencies series. Get a quick lowdown on our roots, our approach, and how we’re dedicated to bettering the world for clients, doctors, patients, and pretty much everyone.